FDA officials to speak at conference

Share this article:
DTC Perspectives will host the third annual Achieving DTC Success conference Nov. 10-11 at the Westin Princeton Hotel in Princeton, N.J.
Among the event's scheduled speakers are two representatives from the FDA's Division of Drug Marketing, Advertising and Communications: Kathryn Aikin, a social science analyst, and Melissa Moncavage, the DTC review group leader. Ed Slaughter, director of market research at Prevention magazine and Lilly's Holly Sullivan, a senior marketing professional on Cialis, also will give presentations. The winners of the Perspectives On Excellence (POE) awards will be announced at an awards dinner on the first evening of the conference.
Bob Ehrlich, chief executive of DTC Perspectives, will address the changing role of DTC in 2005. The discussion will focus on what marketers need to do to face the tough 2005 DTC environment.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...